Year
2023
-
Chiesi Group’s Lamzede Gets FDA Approval for Rare Genetic Disorder
-
Moderna announces interim results from Phase 3 safety and immunogenicity trial of mRNA-1010, vaccine candidate.
-
FDA Accepts Two sNDAs for Merck’s Prevymis
-
Regeneron is off to CHAPLE as FDA starts pozelimab review
-
Modus Therapeutics announces positive topline data from its Phase 1b LPS provocation study evaluating the potential of sevuparin for treatment of sepsis
-
Lagevrio Disappoints in Phase 3 study for Post-Exposure Prevention of COVID-19
-
FDA Approves First Treatment for Geographic Atrophy, Accepts NDA for Same Indication
-
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
-
FDA Approves Austedo XR Extended-Release Tablets for Huntington’s Disease
-
EU Authorizes CSL’s Gene Therapy for Hemophilia B